Table 1.

Participant characteristics

Variable	N (%) or M (SD)
	Content and wireframe review		Iterative pre-pilot
	DFCI (N = 14)	SCC (N = 14)	SCC (N = 7)	DFCI (N = 8)
Female	8 (57%)	7 (50%)	4 (57%)	5 (63%)
Age (years)	54.3 (9.7)	51.6 (12.4)	46.0 (8.9)	52.0 (9.6)
Race/ethnicity
American Indian/Alaska Native		1 (7%)
Black/African American		1 (7%)		1 (13%)
White	14 (100%)	12 (86%)	7 (100%)	7 (88%)
Hispanic			2 (29%)
Current/historical opioid use
Short-acting	13 (93%)	14 (100%)	7 (100%)	8 (100%)
Long-acting	8 (57%)	8 (57%)	4 (57%)	6 (75%)
Cancer type*
Head and neck	3 (21%)	2 (14%)	2 (29%)	1 (13%)
Breast	2 (14%)	1 (7%)		2 (25%)
Upper gastrointestinal				2 (25%)
Colorectal	3 (21%)	2 (14%)	1 (14%)
Lung	3 (21%)	1 (7%)
Hemopoietic	2 (14%)		1 (14%)	1 (13%)
Kidney	2 (14%)	1 (7%)
Prostate		1 (7%)		1 (13%)
Neuroendocrine		1 (7%)
Pancreatic		1 (7%)	1 (14%)
Cervical		1 (7%)	1 (14%)
Ovarian		1 (7%)	1 (14%)
Polycythemia vera		1 (7%)
Other	1 (7%)	1 (7%)		1 (13%)
Received a study phone			5 (71%)	4 (50%)
Rural address	0	3 (21%)	2 (29%)	0

Rurality was identified using zip code analysis of RUCA codes [58]. Some participants were diagnosed with multiple primary cancer types. Samples were recruited from the Stephenson Cancer Center (SCC) in Oklahoma City, OK and the Dana-Farber Cancer Institute (DFCI) in Boston, MA